All Stories

  1. Prognostic impact of socioeconomic status among patients with malignant melanoma of the skin: a population-based study

    Article • Journal of Dermatological Treatment, August 2019, Taylor & Francis

    Omar Abdel-Rahman

  2. Pre-diagnostic body mass index trajectory in relationship to lung cancer incidence and mortality; findings from the PLCO trial

    Article • Expert Review of Respiratory Medicine, August 2019, Taylor & Francis

    Omar Abdel-Rahman

  3. Initial systemic chemotherapeutic and targeted therapy strategies for the treatment of colorectal cancer patients with liver metastases

    Article • Expert Opinion on Pharmacotherapy, July 2019, Taylor & Francis

    Dr anas M. saad, Omar Abdel-Rahman

  4. Impact of current versus former smoking status on the outcomes of non-metastatic non-small cell lung cancer treated with upfront surgery; findings from the National Lung Screening Trial

    Article • Expert Review of Respiratory Medicine, May 2019, Taylor & Francis

    Omar Abdel-Rahman

  5. The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma

    Article • Expert Review of Respiratory Medicine, April 2019, Taylor & Francis

    Omar Abdel-Rahman

  6. Prognostic impact of baseline quality of life status among patients with advanced gastric cancer; results from two randomized studies

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, March 2019, Taylor & Francis

    Omar Abdel-Rahman

  7. Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

    Article • Journal of Hepatocellular Carcinoma, November 2018, Dove Medical Press

    Omar Abdel-Rahman

  8. Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review

    Article • Expert Review of Anticancer Therapy, October 2018, Taylor & Francis

    Omar Abdel-Rahman

  9. Incidence and predictors of 1-year mortality among 9236 breast cancer patients referred for adjuvant chemotherapy

    Article • Future Oncology, October 2018, Future Medicine

    Omar Abdel-Rahman

  10. M-bioscore: proposing a new statistical model for prognostic factors in metastatic breast cancer patients

    Article • Journal of Comparative Effectiveness Research, September 2018, Future Medicine

    Omar Abdel-Rahman

  11. Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials

    Article • Expert Review of Gastroenterology & Hepatology, August 2018, Taylor & Francis

    Omar Abdel-Rahman

  12. The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma

    Article • Canadian Journal of Gastroenterology and Hepatology, August 2018, Hindawi Publishing Corporation

    Omar Abdel-Rahman

  13. Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid: a secondary analysis of a randomized study

    Article • Expert Opinion on Drug Safety, July 2018, Taylor & Francis

    Omar Abdel-Rahman

  14. Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials

    Article • Expert Review of Gastroenterology & Hepatology, July 2018, Taylor & Francis

    Omar Abdel-Rahman

  15. Integrating Systemic Therapies into the Multimodality Treatment of Resectable Colorectal Liver Metastases

    Article • Gastroenterology Research and Practice, June 2018, Hindawi Publishing Corporation

    Omar Abdel-Rahman

  16. Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores

    Article • Future Oncology, June 2018, Future Medicine

    Omar Abdel-Rahman

  17. Outcomes of Surgery as Part of the Management of Metastatic Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology and End Results Database Analysis

    Article • Cancer Investigation, April 2018, Taylor & Francis

    Omar Abdel-Rahman

  18. Assessment of the external validity of the American Joint Committee on Cancer 8th staging system for anal carcinoma

    Article • Current Medical Research and Opinion, March 2018, Taylor & Francis

    Omar Abdel-Rahman

  19. Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review

    Article • Immunotherapy, February 2018, Future Medicine

    Omar Abdel-Rahman

  20. Evaluation of the eighth American Joint Committee on Cancer staging system for malignant melanoma of the skin

    Article • Future Oncology, January 2018, Future Medicine

    Omar Abdel-Rahman

  21. Comparison of three prognostic models for predicting cancer-specific survival among patients with gastrointestinal stromal tumors

    Article • Future Oncology, January 2018, Future Medicine

    Omar Abdel-Rahman

  22. Impact of histological subtype on outcomes of renal cell carcinoma patients

    Article • Journal of Drug Assessment, January 2018, Taylor & Francis

    Omar Abdel-Rahman

  23. Validation of the eighth clinical American Joint Committee on Cancer stage grouping for esophageal cancer

    Article • Future Oncology, December 2017, Future Medicine

    Omar Abdel-Rahman

  24. Dissecting the heterogeneity of stage III non-small-cell lung cancer through incorporation of grade and histology

    Article • Future Oncology, November 2017, Future Medicine

    Omar Abdel-Rahman

  25. Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy

    Article • Therapeutic Advances in Urology, November 2017, SAGE Publications

    Omar Abdel-Rahman

  26. Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review

    Article • Immunotherapy, November 2017, Future Medicine

    Omar Abdel-Rahman

  27. Impact of the staging method on the prognostic utility of the 8th AJCC staging system for non-small-cell lung cancer

    Article • Future Oncology, October 2017, Future Medicine

    Omar Abdel-Rahman

  28. Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review

    Article • Immunotherapy, September 2017, Future Medicine

    Omar Abdel-Rahman

  29. Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma

    Article • Future Oncology, August 2017, Future Medicine

    Omar Abdel-Rahman

  30. Clinical significance of miRNA-autophagy transcript expression in patients with hepatocellular carcinoma

    Article • Biomarkers in Medicine, August 2017, Future Medicine

    Omar Abdel-Rahman

  31. Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis

    Article • Expert Review of Anticancer Therapy, July 2017, Taylor & Francis

    Omar Abdel-Rahman

  32. Impact of liver transplantation on the risk of second malignant tumors among hepatocellular carcinoma patients

    Article • Expert Review of Gastroenterology & Hepatology, July 2017, Taylor & Francis

    Omar Abdel-Rahman

  33. Risk of cardiac death among cancer survivors in the United States: a SEER database analysis

    Article • Expert Review of Anticancer Therapy, June 2017, Taylor & Francis

    Omar Abdel-Rahman

  34. Impact of tumor size on the outcome of patients with small renal cell carcinoma

    Article • Expert Review of Anticancer Therapy, June 2017, Taylor & Francis

    Omar Abdel-Rahman

  35. Subsequent thoracic cancers among patients diagnosed with lung cancer: a SEER database analysis

    Article • Current Medical Research and Opinion, June 2017, Taylor & Francis

    Omar Abdel-Rahman

  36. Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review

    Article • Expert Review of Neurotherapeutics, May 2017, Taylor & Francis

    Omar Abdel-Rahman

  37. Causes of death in long-term lung cancer survivors: a SEER database analysis

    Article • Current Medical Research and Opinion, May 2017, Taylor & Francis

    Omar Abdel-Rahman

  38. Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)

    Article • Drug Design Development and Therapy, March 2017, Dove Medical Press

    Omar Abdel-Rahman, Dr Noha F Rashad

  39. Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?

    Article • Immunotherapy, January 2017, Future Medicine

    Omar Abdel-Rahman

  40. Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review

    Article • Immunotherapy, December 2016, Future Medicine

    Omar Abdel-Rahman

  41. Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis

    Article • Future Oncology, September 2016, Future Medicine

    Omar Abdel-Rahman, Dr Hesham Elhalawani

  42. PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis

    Article • Immunotherapy, September 2016, Future Medicine

    Omar Abdel-Rahman

  43. Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review

    Article • Melanoma Management, September 2016, Future Medicine

    Omar Abdel-Rahman

  44. Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis

    Article • Therapeutic Advances in Medical Oncology, June 2016, SAGE Publications

    Omar Abdel-Rahman

  45. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

    Article • Therapeutic Advances in Respiratory Disease, March 2016, SAGE Publications

    Omar Abdel-Rahman

  46. Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations

    Article • Therapeutic Advances in Respiratory Disease, February 2016, SAGE Publications

    Omar Abdel-Rahman

  47. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis

    Article • Future Oncology, February 2016, Future Medicine

    Omar Abdel-Rahman, Dr Hesham Elhalawani

  48. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside

    Article • Future Oncology, January 2016, Future Medicine

    Omar Abdel-Rahman

  49. Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis

    Article • Future Oncology, December 2015, Future Medicine

    Omar Abdel-Rahman, Dr Hesham Elhalawani

  50. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

    Article • Immunotherapy, November 2015, Future Medicine

    Omar Abdel-Rahman

  51. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis

    Article • Future Oncology, November 2015, Future Medicine

    Omar Abdel-Rahman

  52. Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers

    Article • Therapeutics and Clinical Risk Management, July 2015, Dove Medical Press

    Omar Abdel-Rahman, Dr Hesham Elhalawani

  53. Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis

    Article • Current Medical Research and Opinion, February 2015, Informa Healthcare

    Omar Abdel-Rahman

  54. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis

    Article • Expert Review of Anticancer Therapy, February 2015, Taylor & Francis

    Omar Abdel-Rahman

  55. Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis

    Article • Expert Review of Anticancer Therapy, February 2015, Taylor & Francis

    Omar Abdel-Rahman

  56. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects

    Article • Critical Reviews in Oncology/Hematology, January 2015, Elsevier

    Omar Abdel-Rahman

  57. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis

    Article • Expert Review of Anticancer Therapy, December 2014, Taylor & Francis

    Omar Abdel-Rahman

  58. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis

    Article • Critical Reviews in Oncology/Hematology, December 2014, Elsevier

    Omar Abdel-Rahman

  59. Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review

    Article • Expert Review of Anticancer Therapy, November 2014, Taylor & Francis

    Omar Abdel-Rahman

  60. Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications

    Article • Expert Review of Anticancer Therapy, October 2014, Taylor & Francis

    Omar Abdel-Rahman

  61. Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns

    Article • Expert Opinion on Drug Safety, September 2014, Informa Healthcare

    Omar Abdel-Rahman

  62. RAF signaling in neuroendocrine neoplasms: From bench to bedside

    Article • Cancer Treatment Reviews, September 2014, Elsevier

    Omar Abdel-Rahman

  63. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature

    Article • Journal of Cancer Research and Clinical Oncology, July 2014, Springer Science + Business Media

    Omar Abdel-Rahman

  64. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature

    Article • Critical Reviews in Oncology/Hematology, July 2014, Elsevier

    Omar Abdel-Rahman

  65. Hepatic toxicity of lapatinib

    Article • Expert Opinion on Drug Safety, June 2014, Informa Healthcare

    Omar Abdel-Rahman

  66. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis

    Article • Expert Review of Anticancer Therapy, June 2014, Taylor & Francis

    Omar Abdel-Rahman

  67. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis

    Article • Expert Review of Anticancer Therapy, March 2014, Taylor & Francis

    Omar Abdel-Rahman

  68. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience

    Article • Journal of the Egyptian National Cancer Institute, March 2014, Springer Science + Business Media

    Omar Abdel-Rahman

  69. Sphenoidal esthesioneuroblastoma treated with sequential chemo radiotherapy: A case report and review of the literature

    Article • Journal of Cancer Research and Therapeutics, January 2014, Medknow

    Omar Abdel-Rahman

  70. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside

    Article • Journal of the Egyptian National Cancer Institute, December 2013, Springer Science + Business Media

    Omar Abdel-Rahman

  71. TACE plus sorafenib in HCC

    Article • Digestive Diseases and Sciences, September 2013, Springer Science + Business Media

    Omar Abdel-Rahman

  72. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma

    Article • Medical Oncology, July 2013, Springer Science + Business Media

    Omar Abdel-Rahman